GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Syndax Pharmaceuticals Inc (STU:1T3) » Definitions » Debt-to-Revenue

Syndax Pharmaceuticals (STU:1T3) Debt-to-Revenue : 11.26 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Syndax Pharmaceuticals Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Syndax Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €12.03 Mil. Syndax Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was €318.15 Mil. Syndax Pharmaceuticals's annualized Revenue for the quarter that ended in Dec. 2024 was €29.34 Mil. Syndax Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 was 11.26.


Syndax Pharmaceuticals Debt-to-Revenue Historical Data

The historical data trend for Syndax Pharmaceuticals's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syndax Pharmaceuticals Debt-to-Revenue Chart

Syndax Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.54 0.15 N/A N/A 14.60

Syndax Pharmaceuticals Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A 0.08 0.02 11.26

Competitive Comparison of Syndax Pharmaceuticals's Debt-to-Revenue

For the Biotechnology subindustry, Syndax Pharmaceuticals's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Syndax Pharmaceuticals's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Syndax Pharmaceuticals's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Syndax Pharmaceuticals's Debt-to-Revenue falls into.


;
;

Syndax Pharmaceuticals Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Syndax Pharmaceuticals's Debt-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(12.029 + 318.152) / 22.614
=14.60

Syndax Pharmaceuticals's annualized Debt-to-Revenue for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(12.029 + 318.152) / 29.336
=11.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Dec. 2024) Revenue data.


Syndax Pharmaceuticals Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Syndax Pharmaceuticals's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Syndax Pharmaceuticals Business Description

Traded in Other Exchanges
Address
730 Third Avenue, 9th Floor, New York, NY, USA, 10017
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.

Syndax Pharmaceuticals Headlines

No Headlines